menu search

AMRS / Amyris, ImmunityBio Shares Trading Higher On COVID-19 Vaccine Joint Venture

Amyris, ImmunityBio Shares Trading Higher On COVID-19 Vaccine Joint Venture
Amyris Inc (NASDAQ: AMRS) and ImmunityBio (NASDAQ: IBRX) have completed their previously announced joint venture agreement to accelerate the commercialization of a next-generation COVID-19 vaccine. Upon completion of human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as it is practically possible to deliver. Read More
Posted: Jan 3 2022, 12:50
Author Name: Benzinga
Views: 112325

AMRS News  

Retail investors flock to penny stocks WeWork, Amyris, Proterra

By Reuters
August 11, 2023

Retail investors flock to penny stocks WeWork, Amyris, Proterra

WeWork, a prized startup just four years ago but now a micro-cap, and other penny stocks such as Amyris and Proterra are the latest focus of speculati more_horizontal

AMRS Stock Surges 152% as Amyris Files for Bankruptcy

By InvestorPlace
August 11, 2023

AMRS Stock Surges 152% as Amyris Files for Bankruptcy

Amyris (NASDAQ: AMRS ) stock is rising higher on Friday with heavy trading after the biotechnology company filed for bankruptcy. AMRS stock is bounci more_horizontal

Biotech Company Amyris Files for Bankruptcy

By Investopedia
August 10, 2023

Biotech Company Amyris Files for Bankruptcy

Synthetic biotechnology company Amyris filed for Chapter 11 bankruptcy protection as it restructures, leading its share price to drop more than 70% in more_horizontal

Why Is Amyris (AMRS) Stock Down 67% Today?

By InvestorPlace
August 10, 2023

Why Is Amyris (AMRS) Stock Down 67% Today?

Amyris (NASDAQ: AMRS ) stock is falling on Thursday after the company filed for Chapter 11 bankruptcy protection. According to a press release from A more_horizontal

Amyris Warns Of Potential Bankruptcy - Sell

By Seeking Alpha
August 7, 2023

Amyris Warns Of Potential Bankruptcy - Sell

Cash-strapped specialty renewable products developer Amyris remains on life support by largest shareholder and creditor John Doerr. In recent months, more_horizontal

Is It Time to Buy This Year's Worst-Performing Growth Stocks?

By The Motley Fool
July 11, 2023

Is It Time to Buy This Year's Worst-Performing Growth Stocks?

Not all low-priced stocks are appealing for investment, as some remain too unpredictable even at a lower buy-in price. This is a mixed bag and investo more_horizontal

Amyris: CEO's Exit Has Negative Implications

By Seeking Alpha
July 3, 2023

Amyris: CEO's Exit Has Negative Implications

The resignation of Amyris' CEO is likely to be viewed as a positive by many, but the implications of this are negative. Management turnover and the en more_horizontal

Amyris: Company Separates From Long-Standing CEO Amid Ongoing Restructuring Efforts - Sell

By Seeking Alpha
June 27, 2023

Amyris: Company Separates From Long-Standing CEO Amid Ongoing Restructuring Efforts - Sell

Earlier this month, cash-strapped specialty renewable products developer Amyris announced a strategic transformation program to improve the company's more_horizontal


Search within

Pages Search Results: